NewsBite

Stockhead

More Stories

Stockhead
Break it Down: Invion

Break it Down: Invion

Invion has completed the dosing of six patients in its Phase I/II clinical trial for INV-043, treating non-melanoma skin cancers.

Original URL: https://www.heraldsun.com.au/business/stockhead